Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate

Psychoneuroendocrinology

Volumn 36, Issue 8, 2011, Pages 1209-1216

  Wang, Liang Jen ^a,b   Hsiao, Cheng Cheng ^a,b   Huang, Yu Shu ^a,b   Chiang, Yuan Lin ^a   Ree, Shao Chun ^a   Chen, Yi Chih ^a   Wu, Ya Wen ^a   Wu, Chih Ching ^b   Shang, Zong Yi ^a   Chen, Chih Ken ^a,b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

ADHD; Continuous performance test; Dehydroepiandrosterone; Methylphenidate

Indexed keywords

METHYLPHENIDATE; PRASTERONE;

ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONE DETERMINATION; HUMAN; HYPERACTIVITY; IMPULSIVENESS; LONGITUDINAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALIVA ANALYSIS; SALIVA LEVEL; SCHOOL CHILD; SYMPTOMATOLOGY; TREATMENT DURATION;

AFFECTIVE SYMPTOMS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM AGENTS; CHILD; CHILD, PRESCHOOL; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; SALIVA; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051470737     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.02.014     Document Type: Article

References (41)

1. Aggarwal A., Lillystone D. A follow-up pilot study of objective measures in children with attention deficit hyperactivity disorder. J. Paediatr. Child Health 2000, 36:134-138.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental disorders 2000, American Psychiatric Association, Washington, DC.
3. Baulieu E.E. Dehydroepiandrosterone (DHEA): a fountain of youth?. J. Clin. Endocrinol. Metab. 1996, 81:3147-3151.
4. Biederman J., Faraone S.V. Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder. J. Atten. Disord. 2002, 6(Suppl. 1):S7-16.
5. Biederman J., Mick E., Faraone S.V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am. J. Psychiatry 2000, 157:816-818.
6. Brookes K.J., Hawi Z., Kirley A., Barry E., Gill M., Kent L. Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1531-1535.
7. Cano B., de Oya M., Benavente M., Viturro E., de Oya I., Lopez-Simon L., Fernandez O., Garces C. Dehydroepiandrosterone sulfate (DHEA-S) distribution in Spanish prepuberal children: relationship with fasting plasma insulin concentrations and insulin resistance. Clin. Chim. Acta 2006, 366:163-167.
8. Conners C.K. Conners' Continuous Performance Test II (CPTII) for Windows Technical Guide and Software Manual 2004, MHS, NY.
9. Davies W., Humby T., Kong W., Otter T., Burgoyne P.S., Wilkinson L.S. Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. Biol. Psychiatry 2009, 66:360-367.
10. Epstein J.N., Conners C.K., Hervey A.S., Tonev S.T., Arnold L.E., Abikoff H.B., Elliott G., Greenhill L.L., Hechtman L., Hoagwood K., Hinshaw S.P., Hoza B., Jensen P.S., March J.S., Newcorn J.H., Pelham W.E., Severe J.B., Swanson J.M., Wells K., Vitiello B., Wigal T. Assessing medication effects in the MTA study using neuropsychological outcomes. J. Child. Psychol. Psychiatry 2006, 47:446-456.
11. Epstein J.N., Erkanli A., Conners C.K., Klaric J., Costello J.E., Angold A. Relations between Continuous Performance Test performance measures and ADHD behaviors. J. Abnorm. Child Psychol. 2003, 31:543-554.
12. Golubchik P., Lewis M., Maayan R., Sever J., Strous R., Weizman A. Neurosteroids in child and adolescent psychopathology. Eur. Neuropsychopharmacol. 2007, 17:157-164.
13. Hibel L.C., Granger D.A., Cicchetti D., Rogosch F. Salivary biomarker levels and diurnal variation: associations with medications prescribed to control children's problem behavior. Child Dev. 2007, 78:927-937.
14. Huang Y.S., Chao C.C., Wu Y.Y., Chen Y.Y., Chen C.K. Acute effects of methylphenidate on performance during the Test of Variables of Attention in children with attention deficit/hyperactivity disorder. Psychiatry Clin. Neurosci. 2007, 61:219-225.
15. Jensen P. Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder. J. Atten. Disord. 2002, 6(Suppl 1):S45-S56.
16. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:980-988.
17. Kushnir M.M., Blamires T., Rockwood A.L., Roberts W.L., Yue B., Erdogan E., Bunker A.M., Meikle A.W. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 2010, 56:1138-1147.
18. Lee M.S., Yang J.W., Ko Y.H., Han C., Kim S.H., Joe S.H., Jung I.K. Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder. Child Psychiatry Hum. Dev. 2008, 39:201-209.
19. Lurie S., O'Quinn A. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. J. Neuropsychiatry Clin. Neurosci. 1991, 3:41-50.
20. Maayan R., Yoran-Hegesh R., Strous R., Nechmad A., Averbuch E., Weizman A., Spivak B. Three-month treatment course of methylphenidate increases plasma levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in attention deficit hyperactivity disorder. Neuropsychobiology 2003, 48:111-115.
21. Madaan V., Daughton J., Lubberstedt B., Mattai A., Vaughan B.S., Kratochvil C.J. Assessing the efficacy of treatments for ADHD: overview of methodological issues. CNS Drugs 2008, 22:275-290.
22. MBH Gesellschaft Für Immunchemie Und Immunbiologie Luminescence Immunoassay for the quantitative determination of DHEA in human saliva and serum 2007, IBL, Hamburg, Germany.
23. McAlonan G.M., Cheung V., Chua S.E., Oosterlaan J., Hung S.F., Tang C.P., Lee C.C., Kwong S.L., Ho T.P., Cheung C., Suckling J., Leung P.W. Age-related grey matter volume correlates of response inhibition and shifting in attention-deficit hyperactivity disorder. Br. J. Psychiatry 2009, 194:123-129.
24. Monnet F.P., Mahe V., Robel P., Baulieu E.E. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-d-aspartate in the rat hippocampus. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:3774-3778.
25. Netherton C., Goodyer I., Tamplin A., Herbert J. Salivary cortisol and dehydroepiandrosterone in relation to puberty and gender. Psychoneuroendocrinology 2004, 29:125-140.
26. Overtoom C.C., Verbaten M.N., Kemner C., Kenemans J.L., van Engeland H., Buitelaar J.K., van der Molen M.W., van der Gugten J., Westenberg H., Maes R.A., Koelega H.S. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behav. Brain Res. 2003, 145:7-15.
27. Pollak Y., Shomaly H.B., Weiss P.L., Rizzo A.A., Gross-Tsur V. Methylphenidate effect in children with ADHD can be measured by an ecologically valid continuous performance test embedded in virtual reality. CNS Spectr. 2010, 15:125-130.
28. Rapport M.D., Stoner G., DuPaul G.J., Kelly K.L., Tucker S.B., Schoeler T. Attention deficit disorder and methylphenidate: a multilevel analysis of dose-response effects on children's impulsivity across settings. J. Am. Acad. Child Adolesc. Psychiatry 1988, 27:60-69.
29. Riccio C.A., Waldrop J.J., Reynolds C.R., Lowe P. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin. Neurosci. 2001, 13:326-335.
30. Robel P., Baulieu E.E. Neurosteroids: biosynthesis and function. Crit. Rev. Neurobiol. 1995, 9:383-394.
31. Shao J., Zhong B. Last observation carry-forward and last observation analysis. Stat. Med. 2003, 22:2429-2441.
32. Spencer T.J., Biederman J., Harding M., O'Donnell D., Faraone S.V., Wilens T.E. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?. J. Am. Acad. Child Adolesc. Psychiatry 1996, 35:1460-1469.
33. Spencer T.J., Biederman J., Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J. Pediatr. Psychol. 2007, 32:631-642.
34. Strous R.D., Spivak B., Yoran-Hegesh R., Maayan R., Averbuch E., Kotler M., Mester R., Weizman A. Analysis of neurosteroid levels in attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 2001, 4:259-264.
35. Swanson J.M., Gupta S., Williams L., Agler D., Lerner M., Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:1306-1314.
36. Symonds C.S., Gallagher P., Thompson J.M., Young A.H. Effects of the menstrual cycle on mood, neurocognitive and neuroendocrine function in healthy premenopausal women. Psychol. Med. 2004, 34:93-102.
37. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 1999, 401:63-69.
38. Wang L.J., Huang Y.S., Hsiao C.C., Chiang Y.L., Wu C.C., Shang Z.Y., Chen C.K. Salivary dehydroepiandrosterone, but not cortisol, is associated with attention deficit hyperactivity disorder. World J. Biol. Psychiatry. 2011, 12:99-109.
39. Weizman R., Dick J., Gil-Ad I., Weitz R., Tyano S., Laron Z. Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. Life Sci. 1987, 40:2247-2252.
40. Wolf O.T., Kudielka B.M., Hellhammer D.H., Hellhammer J., Kirschbaum C. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology 1998, 23:617-629.
41. Wolkowitz O.M., Reus V.I., Keebler A., Nelson N., Friedland M., Brizendine L., Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry 1999, 156:646-649.